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Abstract
Background: Prognosis of medically treated trigeminal neuralgia patients is assumed to be poor, but the evidence
is lacking. Thus, prospective real-life studies of medical management of trigeminal neuralgia are warranted.
Methods: This was an observational study. Patients were consecutively enrolled in a structured management
program at a specialist centre for facial pain. Optimisation of medical treatment, physiotherapy, psychotherapy, and
advice from trained nurses, were parts of the program. Medically intractable patients were referred for
neurosurgery. Data-collection was prospective using standardised schemes and patient surveys. The aim was to
describe the two-year outcome of medical treatment at the specialist centre. The primary outcome was a 50%
reduction in the overall burden of pain according to a Numerical Rating Scale (NRS) after two years.
Results: A total of 186 primary TN patients were enrolled in the program of which 103 patients remained medically
managed and completed the two-year follow-up. Fifty patients were treated surgically within the first two years of
follow-up. Half of the medically managed patients (53 (51%)), had more than a 50% reduction in the overall burden
of pain over the two-year period. The overall burden of pain on NRS decreased from mean 5.34 to 3.00, p < 0.01.
There was no significant association between primary outcome and sex, depression and/or anxiety, concomitant
persistent pain, or neurovascular contact with morphological changes of the trigeminal nerve.
Conclusions: Patients with trigeminal neuralgia improve over a two-year period when enrolled in a structured
medical management program. Optimisation of drug treatment, continuous advice and education and support by
the multidisciplinary team, referral of the medically intractable patients for surgery or the natural history of the
disease, can be some of the reasons for the improvement. The favourable prognosis provides hope and optimism
for medically managed TN patients.
Trial registration: Current study was observational, and patients were offered standard clinical care and laboratory
workups according to current American Academy of Neurology and European Federation of Neurological Societies
treatment guidelines. The study has been registered at ClincalTrials.gov. ID: NCT03838393.
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Introduction
Trigeminal neuralgia (TN) is a facial pain disorder char-
acterised by recurrent paroxysms of severe unilateral
pain distributed in one or more branches of the trigemi-
nal nerve [1]. The natural history of TN is commonly as-
sumed to be progressive and the prognosis of the disease
to be poor with slow deterioration over time [1–3].
However, the findings in more recent studies do not
confirm the progressive nature of the disease [4–7] and
the natural history is not fully elucidated. Several studies
describe a good prognosis for patients treated neurosur-
gically [8–10]. However, only a few high-quality cohort
studies have investigated the prognosis of TN when
treated medically [4, 7].
Considerable expertise is necessary for proper medical
management of TN because the drugs are unspecific,
mostly antiepileptics, and often have to be administered
in a high dose to control the pain [11]. Furthermore,
the scientific evidence for drug treatment of TN is
weak [11, 12], and the treatment is often hampered
by insufficient effect, pharmacological interaction, and
side-effects [12, 13].
Randomised controlled trials are the gold standard for
assessment of efficacy and tolerability of drug treatment
[14]. Such trials are usually short-term trials enrolling
highly selected patients and thus may both over- and
underestimate the efficacy of drug treatment in a
real-life setting [15, 16]. Moreover, these trials do not
take other important factors into consideration when it
comes to the optimal management of TN over time.
This includes finding the suitable drug and dose for the
individual patient, continuous optimisation of drug treat-
ment according to disease activity and side-effects [11],
and the value of education and continuous advice and
support. Thus, to investigate the value of the various
treatment options and to describe the prognosis of the
disease when medically managed, real-life studies are
warranted [17].
This study aimed to provide evidence concerning the
real-life efficacy of medical management of TN when di-
rected by specialists. Additionally, the aim was to inspire
other neurological centres to improve their TN manage-
ment programs to ensure the best possible care for this
patient group. We hypothesised that the two-year prog-
nosis in a group of medically managed TN patients en-
rolled in a structured multidisciplinary management
program was favourable, defined as a 50% reduction of
the overall burden of pain over a two-year period.
Material and methods
This study was a prospective, observational study of TN
patients enrolled in a structured multidisciplinary
management program at the Danish Headache Center
(DHC), as previously described in detail [18]. The
program was introduced in May 2012 and was based on
the standard clinical care and laboratory workups ac-
cording to current guidelines [11]. The DHC is a na-
tional centre of excellence that treats approximately 100
new TN patients per year.
Description of the cohort
Newly referred TN patients seen between May 2012 and
December 2015 were enrolled consecutively and
followed-up systematically. Inclusion criteria were: re-
cordings of the intensity of pain at enrolment of the
programme (baseline recording), a two-year assessment
(end-point recording), and effect and side-effects of drug
treatment (at baseline and endpoint). The exclusion cri-
teria were: initiation of medical treatment at the DHC
before May 2012, neurosurgical treatment of TN within
the two-year follow-up, and incomplete two-year
follow-up. The number of patients enrolled in the inclu-
sion period determined the sample size.
The diagnostic criteria used in this study were the beta
version of the 3rd edition of the International Classifica-
tion of Headache Disorders (ICHD-3-beta) [19]. Until
the publication of IHCD-3-beta, ICHD 2 [20] criteria
were used. According to the ICHD-3 classification [1],
this study included patients with both idiopathic and
classical TN; in this paper termed primary TN.
Outpatient visits
At enrolment, all medically managed patients were of-
fered five fixed visits within a two-year period.
Follow-up regime has previously been described in detail
[18]. In short, the patients visits were: Initial visit
(clinical interview, clinical and paraclinical examinations,
diagnosis and treatment, information concerning
pharmacological, non-pharmacological and neurosurgical
treatment options (verbal and written)); and follow-up
visits at approximately 3 (2–4) months, 9 (7–11) months,
15 (12–18) months and 24 (21–28) months after their ini-
tial visit. At the follow-up visits, the treating physician
evaluated treatment effect and, in line with the inter-
national guidelines [11], encouraged patients to adjust the
dosage of medication according to their burden of pain.
The need for referral to neurosurgical treatment was eval-
uated continuously. The neurosurgical options were
microvascular decompression, balloon compression and
glycerol blockade. If patients were neurosurgically treated
they followed a slightly different follow-up regime, as de-
scribed previously [18]. Between the follow-up visits, the
patients could call a trained staff-nurse, with questions
concerning dose adjustment, change of drugs, side-effects
or other concerns regarding TN. Therapy sessions with a
trained DHC psychologist and/or with a physiotherapist
where offered if needed. Consultations with a
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neurosurgeon were also offered if the patients wanted
in-depth information about possibilities for surgery.
At the initial visit, a routine physiological and neuro-
logical examination was performed with a special focus
on the trigeminal sensory function, as previously
described in detail [18].
Neuroimaging
A 3.0 Tesla MRI scan was conducted according to a TN
protocol [21]. The TN protocol was pre-defined for the
trigeminal nerve to exclude secondary cause of TN and
to ensure evaluation of the neurovascular relations, de-
gree, localisation, and type of neurovascular contact if
any. Patients that suffered from claustrophobia, severe
obesity or had a pacemaker were offered an MRI scan in
an open 1.5 Tesla scanner. These scans were without the
predefined TN protocol. All scans were evaluated by the
same experienced neuroradiologist (FW), who was
blinded to the pain side.
Data collection
Assessments were conducted by a neurologist or
highly trained fellow in neurology at the DHC at all
visits. At the initial visit, a standardised purpose-built
semi-structured interview was performed by a
highly-trained fellow in neurology, supervised by a
senior neurologist. At the subsequent follow-up visits,
the patients were assessed by the same senior
neurologist. For a detailed description of the
semi-structured interview see Additional file 1. At the
initial interview and the assessments, the following
was evaluated; a) the overall burden of pain was re-
corded on a Numeric Rating Scale (NRS). Overall
burden of pain was defined as the patient’s
self-perceived burden of pain (global impression of
pain intensity and frequency of attacks) on average
on a scale from 0 to 10, over the last month; b) effect
of current drug treatment was according to the
Barrow Neurological Institute pain scale (BNI) [22],
assessed over the last month; c) daily dosage and
side-effects of current TN drugs. The evaluations
from the assessments were given verbally by the pa-
tients and registered in standardized schemes filled
out by the physician.
A self-complete patient survey was mailed to the pa-
tients two years after their initial visit. If the patients did
not return the questionnaire, a reminder was mailed to
them again 26–27months after enrollment. If they did
not return the second questionnaire, data was registered
as missing. The survey included 21 qualitative and
quantitative questions, corresponding the assessment
schemes, concerning; overall burden of pain, pain qual-
ity, current treatment and satisfaction with treatment.
Satisfaction levels were registered on a 7-point Likert
Scale, anchored at 1 = very dissatisfied and 7 = very satis-
fied. For the analysis, the patients were considered as
satisfied if 5–7 was reported on the scale, while the pa-
tients were regarded as dissatisfied if 1–3 was reported
on the scale. The patients were regarded as neither satis-
fied or dissatisfied if they reported 4 on the scale. See
Additional file 2 for a detailed description.
Data from the control schemes and questionnaires
were used to evaluate the outcome. If there was dis-
agreement between the two-year follow-up assessment
and the patient survey, data from the follow-up scheme
was reported in this study.
Outcome measures
The primary outcome was a good outcome according to
the overall burden of pain NRS, i.e. the number of
patients who had a reduction of minimum 50% on the
NRS two years after enrolment in the management
program compared with baseline. NRS was anchored at
0 = no burden of pain and 10 = worst possible burden of
pain. To grade the burden of pain on the NRS, the scale
was subcategorised into NRS 0 = no burden of pain,
NRS 1–4 =mild burden of pain, NRS 5–7 =moderate
burden of pain, NRS 8–10 = severe burden of pain [23].
If the patient did not take any medication and reported
NRS = 0, the pain was regarded as in remission.
The secondary outcomes were; a) poor outcome de-
fined as no reduction of the overall burden of pain NRS
over the two-year follow-up period. NRS was anchored
as described above, and b) good treatment effect accord-
ing to BNI defined as the number of patients who re-
ported BNI level 0, I or II two years after enrolment.
BNI I = Very good effect: No pain, BNI II = Good effect:
Occasional pain that does not, or only occasionally, re-
duce my quality of life, BNI III = Limited effect: Daily
pain with a moderate reduction of my quality of life, BNI
IV = Insufficient effect: Daily episodes with severe pain
which significantly reduce my quality of life. If patients
were not taking any TN drugs, BNI was registered as
BNI = 0. Patients who were not taking any medication
(BNI = 0) were subdivided into two groups a) patients in
remission b) patients without medical treatment but not
pain-free.
Statistical analyses
Continuous and ranked data are summarized by descrip-
tive statistics. Categorical variables are presented with
frequency distributions (N, %) and with 95% confidence
limits (Cl). McNemar’s, Chi-square and Fisher’s test were
used to assess associations of categorical variables. Non-
parametric testing (Wilcoxon signed-rank test) was used
to determine the significance of differences in reported
outcome measures, e.g. NRS and BNI, between baseline
and endpoint assessments.
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A multivariate logistic regression analysis with back-
ward stepwise selection was used to test for associations
between a subset of predefined variables and good out-
come. The same multivariate logistic regression analysis
was also conducted to test for associations between a
subset of predefined variables and poor outcome.
Variables were retained in the regression model if a
significant association (p < 0.05) was found. Variables
with no significant association with outcome were
excluded sequentially. The predefined independent
variables were sex (male vs. female), anxiety and/or
depression (yes vs. no), disease duration (≥ 5 years vs. < 5
years), degree of neurovascular contact at MRI (with vs.
without morphological changes of the trigeminal nerve)
and pain quality (with concomitant persistent pain vs.
purely paroxysmal pain). In a previous study, which in-
cluded a subset of the patients also included in the current
study, we found a strong association between the male sex
and a neurovascular contact with morphological changes
[21]. Thus, the multivariate logistic regression model was
controlled for this confounding interaction.
To test for associations between a good outcome and
the variables; suffering from other headaches, suffering
from other chronic pain conditions, hypertension,
response to sodium-channel blockers, and findings of
sensory abnormalities of the trigeminal nerve found at
the neurological examination, we used 2 × 2 contingency
chi-square test or Fisher’s exact test.
If more than 10% of the clinical data from the
semi-structured interview or two-year assessments were
missing, the patient was excluded from the analyses.
Missing data were considered missing at random, based
on the assumption that missingness was independent of
the demography, treatment, and pain level. P-values are
reported as two-tailed with a level of significance of 5%.
Analyses were carried out using SAS 9.4 (SAS Institute
Inc., Cary, NC, USA).
Results
From May 2012 to December 2015, 223 patients were
enrolled in the management program. A total of 186
patients were diagnosed with primary TN and 37 pa-
tients with secondary TN (Fig. 1). Of the 186 primary
TN patients, 50 patients (27%) were treated surgically,
i.e. underwent either MVD, glycerol blockade or balloon
compression, within the first two years of their
follow-up. The mean time from the initial visit to
surgery was 217 days, range 16–710 days. The reasons
for discontinuation of medical treatment was due to lack
of efficacy or intolerable side effects. Thirty-three pa-
tients were lost to follow-up or excluded from the study.
A total of 103 patients, (72 women and 31 men) were
included in the study.
The male: female ratio was 1:1.75. The mean age at
onset was 52.5, range 12–81 years. The mean duration
of the disease at the initial visit was 4.4 years, range
Fig. 1 Flowchart of included patients
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0–32 years. The full demographical data, including the
data of the patients that were referred for neurosur-
gery < 24 months after their initial visit, is shown in
Table 1.
Primary outcome measure
The overall burden of pain was reduced from mean NRS
5.34 (Cl 4.79–5.90) to 3.00 (Cl 2.47–3.53), p < 0.001.
Two years after enrolment 53 patients (51%) had a good
outcome, i.e. a minimum reduction of 50% in the overall
burden of pain on NRS, compared with baseline. Signifi-
cantly more patients reported no overall burden of pain
(NRS 0) (16 vs. two patients) and mild burden of pain
(NRS 1–4) (63 vs. 38 patients) at their two-year assess-
ment compared to baseline (p < 0.001 and p = 0.002, re-
spectively). A severe burden of pain (NRS 8–10) was
reported by fewer patients (7 vs. 25 patients) at their
two-year assessment compared to baseline (p < 0.001).
The number of patients with a moderate burden of pain
was unchanged (38 patients vs. 22 patients (p = 0.06))
(Table 2).
Secondary outcome measures
A poor outcome was reported by 33 (32%), of whom 24
patients (23%) reported no changes in the overall burden
of pain, and nine patients (9%) experienced a worsening
of the overall burden of pain, over time.
Of the 16 patients who reported moderate or severe
burden of pain at their two-year assessment, four pa-
tients underwent microvascular decompression after the
two-year assessment. Seven patients were satisfied with
their drug treatment, despite the increase of burden of
pain during the follow-up. Two patients were referred to
neurosurgical consultation but wanted time to consider
the pros and cons for surgery. One patient had
co-existing severe rhinitis at the time of assessment that
might have worsened the TN. Thus, she was not consid-
ered a candidate for surgery, at the time. The reason for
Table 1 Demographics and comorbidities
Characteristic 24 months
medical follow-up
Surgical treatment < 24 months
after 1st outpatient visit
p-value
N (%) 95% Cl mean N (%) 95% Cl mean
Demographics
Total number of patients 103 (67) 50 (33)
Women 72 (70) 60–78 28 (56) 21–34 0.13a
Current age 57.2 54.3–60.1 61.8 57.8–65.8 0.069b
Age at onset, mean, years 52.5 49.7–55.3 54.0 49.8–58.2 0.58b
Disease duration, mean, years 4.4 3.4–5.5 6.2 4.7–7.8 0.10b
Clinical characteristics
Right-sided pain 60 (58) 49–68 26 (52) 37–66 0.42a
Bilateral pain 8 (7) 3–15 0 (0) n/a 0.055c
Concomitant persistent pain 55 (53) 43–63 26 (52) 37–66 0.87a
Localization of pain
V1 3 (3) 0–9 1 (2) 0–10 1.00c
V2 19 (18) 2–26 6 (12) 5–24 0.44a
V3 20 (19) 13–28 15 (30) 19–44 0.21a
V1+ 2 9 (9) 5–16 5 (10) 4–22 0.80a
V2 + 3 37 (36) 27–46 15 (30) 17–45 0.59a
V1+ 2+ 3 15 (15) 9–23 8 (16) 8–29 0.82a
Comorbidities
Hypertension 32 (31) 22–40 15 (30) 17–45 0.89a
Other chronic pain conditions 11 (11) 6–17 9 (18) 9–31 0.17a
Depression and/or anxiety 15 (15) 8–23 7 (14) 6–29 0.89a
Cardiovascular disease 8 (7) 4–14 8 (16) 7–29 0.20a
Tension type headache, migraine or cluster headache 24 (22) 15–31 7 (14) 6–29 0.26a
Demographics of patients with at least 24 months medical follow-up and patients who were referred for surgery < 24months after initial outpatient visit. aChi
square b Unpaired t-test c Fishers exact test. n/a = not applicable. P < 0.05 was considered significant
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not undergoing neurosurgery was unknown in two
patients.
At the two-year follow-up, there was a median im-
provement of 1 on the BNI scale, (p < 0.001), reduced
from a median of 2 (SD 1.31) to 1 (SD 1.16) on the BNI
scale. Significantly more patients reported a good treat-
ment effect according to BNI (BNI 0, I or II) at the
two-year assessment (85 patients (83%)), compared with
baseline (53 patients (53%)), (p < 0.001) (Table 3).
Association between clinical characteristics and outcome
Patients with at least five years disease duration had 2.5
times higher odds of a good two-year outcome com-
pared to patients with a disease duration of 0–4 years
(Cl 1.06–5.79), p = 0.036. The regression model did not
show any significant association between good outcome
and sex, morphological changes of the trigeminal nerve
on the MRI, depression and/or anxiety, or concomitant
persistent pain (Table 4). Post hoc analysis showed that
suffering from other chronic pain diseases was associ-
ated with a reduced chance of good outcome, (OR 0.13,
Cl 0.03–0.63), p = 0.009. Post hoc analysis showed no
association between good outcome and the following
clinical characteristics: bilateral pain (p = 0.48);
suffering from other headaches (p = 0.90); hypertension,
(p = 0.66); depression/anxiety (p = 0.11) or age < 40 at
onset (p = 0.88). (Additional file 3). Poor outcome was
not associated with any of the before mentioned clinical
variables.
Clinical characteristics and drug treatment
The clinical characteristics of the medically treated pa-
tients did not differ from the characteristics of the pa-
tients who were referred to neurosurgery before their
two-year follow-up (Table 1). The neuroimaging findings
of the trigeminal nerve were also similar in the two
groups (Table 5).
Changes in the pharmacological treatment, i.e. changes
in dosages or types of drugs were carried out in 96
(93%) of the enrolled patients (initial visit compared to
two-year assessment). Seven (7%) patients did not take
any medication neither at baseline nor the two-year
assessment. They continued their follow-up at the DHC
due to the treatment of other coexisting headaches,
Table 2 Changes in overall burden of pain over the last month according to Numeric Rating Scale
Overall burden
of pain (NRS)
Grading of overall
burden of pain
Overall burden of pain
initial assessment N (%)
Mean overall burden of
pain - initial assessment (Cl)
Mean change in overall burden
of pain at two-year assessment (Cl)
p-value#
0 No burden of pain 2 (2) 0 0.5 (−5.85–6.85) 0.5
1 Mild burden of pain 10 (10) 2.58 (2.18–2.98) −2.32 (−3.27- -1.36) 0.003
2 9 (9)
3 6 (6)
4 13 (13)
5 Moderate burden of pain 16 (16) 5.92 (5.63–6.21) −0.97 (−1.63 - - 0.32) < 0.001
6 9 (9)
7 13 (13)
8 Severe burden of pain 10 (10) 9.2 (8.72–9.52) −5.60 (−6.83 - - 4.37) < 0.001
9 2 (2)
10 13 (13)
N = 103. NRS = Numeric Rating Scale, #Wilcoxon Signed Rank test. Cl = 95% confidence limits. P < 0.05 was considered significant
Table 3 Barrow Neurological Institute pain intensity score at baseline and at two-year assessment
Score Pain description Initial assessment
N (%)
Two-year assessment
N (%)
Median change
of BNI
p-value#
BNI 0 No medication needed at the time of assessment 16 (16) * 29 (28) ** 0 0.25
BNI I Very good effect: No pain 17 (17) 28 (27) 0 0.30
BNI II Good effect: occasional pain that does not,
or only occasionally, reduce my quality of life
20 (19) 28 (27) - 1 0.078
BNI III Limited effect: Daily pain with a moderate
reduction of my quality of life
35 (34) 13 (13) - 1 < 0.001
BNI IV Insufficient effect: Daily episodes with severe
pain which significantly reduce my quality of life
15 (15) 5 (5) −2 < 0.001
N = 103. BNI = Barrow Neurological Institute pain intensity score. # Wilcoxon Signed Rank test. *Two patients were in remission (no pain) while 18 were reporting
pain on the VNRS (not pain-free). ** Nineteen patients were in remission (no pain) while 10 were reporting pain on the VNRS (not pain-free). Thirty-seven patients
(36%) reported unchanged BNI level, while 14 (14%) patients had a worsening in BNI over the two-year follow-up period. P < 0.05 was considered significant
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primarily migraine and tension-type headache. At the
initial assessment significantly more patients, 97 patients
(85%), were using TN drugs, compared to 74 patients
(72%) who were using TN drugs at their two-year assess-
ment, (p < 0.001). The most frequently used drugs at the
initial visit were carbamazepine (29 patients (28%)) and
gabapentin (29 patients (28%)) (Table 6). At the
two-year assessment, oxcarbazepine was the most
frequently used drug (30 patients (29%)).
The median dose of carbamazepine at the first visit
was 600 mg (range 100–1600mg) and 800 mg (range
200–1400mg) at the two-year assessment, (p = 0.12).
The median dose of oxcarbazepine at baseline was 1200
mg (range 300–2400 mg) and 900 mg (range 300–2700
mg) at the two-year assessment (p = 0.18). The median
dose of gabapentin at baseline was 1600mg (range 600–
4500 mg) and 2100 mg (range 600–3600 mg) at the
two-year assessment (p = 0.59) (Table 6).
Combination therapy with two or more drugs was
used in 22 (21%) patients at baseline. The most frequent
combinations were carbamazepine and gabapentin (4
patients), or oxcarbazepine and gabapentin (4 patients).
At the two-year assessment 25 patients (24%) used
combination therapy. The most frequently used
combinations were oxcarbazepine and gabapentin (7 pa-
tients) and carbamazepine and gabapentin (6 patients).
There was a significant increase in the number of pa-
tients who were not taking any TN drugs at the
two-year assessment (31 patients (29%)) compared with
baseline (17 patients (17%)), (p < 0.038).
During the follow-up period, the type or number of
drugs was changed in 62 (60%) patients of whom the
treatment was discontinued in 14 patients (23%), drug
treatment was initiated in four patients (6%), while the
type of drug was changed in 22 patients (36%). Combin-
ation therapy was altered to monotherapy in 6 patients
(10%), combination therapy was initiated in 14 patients
(23%), and combination therapy with three or more
drugs was reduced to two drugs in 2 patients (3%).
Patient satisfaction
The patient survey was returned by 52 (50%) patients.
Of these, 45 patients answered the questions concerning
satisfaction with the treatment and level of information
given at the DHC. Regarding satisfaction concerning the
treatment; 9 (20%) patients were unsatisfied, 4 (9%)
patients were neither satisfied nor unsatisfied, while 32
(71%) patients were satisfied. Concerning the level of
Table 4 Associations between clinical characteristics and good outcome
Prognostic variable OR 95% Cl p-value
Disease duration (≥ 5 years vs. < 5 years) 2.5 1.1–6.0 0.036
Anxiety and/or depression (yes vs. no) 0.4 0.1–1.2 0.084
Neurovascular contact with morphological changes found on MRI (yes vs. no) 0.8 0.3–2.0 0.68
Sex (man vs. woman) 1.2 0.5–3.3 0.68
Purely paroxysmal pain (yes vs. no) 0.9 0.4–2.3 0.88
N = 103 TN patients, of whom 53 had a good outcome. Good outcome = 50% reduction of the overall burden of pain according to NRS. The analysis of the
association between the prognostic variable and good outcome was done by multiple logistic regression with back-wards elimination. p-values are reported as
two-tailed with a level of significance of 5%. OR = odds ratio; Cl = 95% confidence limits
Table 5 Baseline neuroimaging findings
MRI findings
24 months medical follow-up Surgical treatment < 24months
after 1st outpatient visit
P-value
N = 95* N = 50
N (%) 95% Cl N (%) 95% Cl
Grade Neurovascular contact with morphological changes**
(Classical trigeminal neuralgia)
37 (39) 28–48 25 (50) 36–65 0.27
Neurovascular contact without morphological changes
(Idiopathic trigeminal neuralgia)
44 (46) 36–57 22 (44) 30–59 0.93
No neurovascular contact (Idiopathic trigeminal neuralgia) 14 (15) 9–25 3 (6) 1–17 0.17a
Type of contact Contact caused by one or more arteries 38 (40) 30–51 28 (56) 44–74 0.10
Contact caused by one or more veins 24 (24) 17–36 7 (14) 6–27 0.17
Mixed contact (artery and vein) 19 (20) 12–29 12 (24) 14–40 0.73
The protocol and evaluation of the MRI scans were identical for patients with unilateral and bilateral pain. Results of the evaluations of patients with bilateral pain
were included in the analysis of MRI findings only if the degree and type of contact between the trigeminal nerve and adjacent vessel(s), were the same on both
sides. *Four patients with bilateral pain were excluded due to differences between sides. Four patients did not have a MRI according to protocol. **Displacement
and/or atrophy of the trigeminal nerve. aFisher’s exact test. CL = 95% confidence limits
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information: 6 (13%) patients were unsatisfied, 13 (13%)
patients were neither satisfied nor unsatisfied, while 33
(73%) patients were satisfied.
Lost to follow-up
Thirty-three patients (24%) were lost to follow-up.
This was due to; a) Satisfied with current treatment
and did not want further follow-up, n = 9, b) Did not
have endpoint NRS recordings n = 6, c) Not satisfied
with the treatment and did not want further
follow-up, n = 4, d) Suffered from other diseases not
related to TN (cancer, pregnant, pulmonary, urinary),
n = 4, e) Dead not related to TN, n = 4, f ) No
out-patient visits, for unknown reasons, n = 2, g) Only
interested in surgical treatment and discontinued fol-
low up at DHC, n = 2, h) Moved to another country,
n = 1, i) No further treatment options according to
treating physician at 1st out-patient visit, n = 1.
Non-pharmacological treatment
A standardised collection of data concerning the use of
non-medical treatment have not been conducted in this
study. However, we estimate that 10% of the patients
have used the non-pharmacological treatment offers
(physiotherapists or phycologists) and estimate that over
90% of the patients have talked to the specially trained
nurses. Future studies are to be conducted.
Discussion
This real-life prospective study demonstrates that TN
patients enrolled in a structured multidisciplinary med-
ical treatment program improve over two years with half
of the patients having more than 50% reduction in the
overall burden of pain. Findings are in line with a previ-
ous prospective study with a shorter follow-up (3–9.5
months), where 68% of the patients reported a 50% re-
duction of pain [7]. The reasons for this favourable prog-
nosis are probably several; individualisation of drug
treatment, optimisation of dose, education and support
of the patients and appropriate referral of medically in-
tractable patients to surgery. Natural history of the dis-
ease or regression towards the mean could play a role.
Finding the right drug and dose for the individual patient
Our results could indicate that a structured program
directed by specialists is effective. It is likely that indivi-
dualised drug treatment and proper dose adjustments
play a role. Almost all the enrolled patients underwent
individual adjustment and/or change of drug during the
time of follow-up. In the group of patients who were in
current drug treatment, the dosage of medication was
stable as well as there were no significant changes in the
use of specific types of drugs. An increased number of
patients were without drug treatment as well as there
was an increment in the number of patients with very
good or good effect of the drug treatment, during the
follow-up.
Table 6 Drugs used for trigeminal neuralgia at initial and follow-up assessments
Initial
assessment
(n = 103) *
Dose Range
(initial)
3 months
assessment
(n = 60)
6 months
assessment
(n = 71)
12 months
assessment
(n = 60)
Two-year
assessment
(n = 103)
Dose range
(two-year)
P-value#
N (%) Cl mg N (%) Cl N (%) Cl N (%) Cl N (%) Cl mg
Carbamazepine 29 (28) 19–37 100–1600 22 (36) 24–47 22 (31) 21–43 15 (25) 14–37 20 (19) 12–28 200–1400 0.13
Oxcarbazepine 20 (19) 12–28 300–2400 20 (33) 22–46 18 (25) 16–37 18 (30) 19–43 30 (29) 21–39 300–2700 0.076
Gabapentin 29 (28) 20–37 600–4500 14 (23) 12–33% 17 (24) 14–36 12 (20) 10–32 24 (23) 15–32 600–3600 0.33
Pregabalin 8 (8) 3–13 150–600 7 (12) 3–19 2 (3) 0–9 6 (10) 4–21% 7 (7) 3–14 150–600 1.00
Baclofen 4 (4) 0–10 15–70 – – – 1 (1) 0–5 40 N/A
Valproate 4 (4) 0–10 500–1200 1 (2) 0–5 1 (1) 0–4 1 (2) 0–5 – – N/A
Tricyclic antidepressants 3 (3) 0–8 100–200 1 (2) 0–5 2 (2) 0–6 2 (3) 1–9 4 (4) 0–10 40–100 1.00
Lamotrigine 3 (3) 0–8 250–800 4 (6) 3–13 4 (6) 0–14 3 (5) 0–14 7 (7) 2–14 125–700 0.22
Phenytoin 1 (1) 0–5 50 – – – – – N/A
Morphine-like drugs 2 (2) 0–7 200 – – – 2 (2) 0–7 200 N/A
Paracetamol 4 (4) 0–10 1000–4000 1 (2) 0–5 – 1 (2) 0–5 3 (3) 0–8 1000–4000 1.00
NSAID 2 (2) 0–7 400–1200 2 (3) 1–9 – 1 (2) 0–5 1 (1) 0–5 Md N/A
Verapamil 1 (1) 0–7 480 – – 1 (2) 0–5 – – N/A
Eslicarbazepine – – – – – 1 (1) 0–7 800 N/A
Levetiracetam – – – – – 1 (1) 0–7 1500 N/A
aFishers exact test. *Represents the drugs that patients reported at their initial visit at DHC, i.e. the drugs they were using at the time of referral. #Mc Nemars test
based on data from initial vs. two-year assessment. CL = 95% confidence limits. N/A = not applicable, Md =missing data
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Non-pharmacological education and support
Although drug treatment is a cornerstone in TN
management, patient-centered care including non-
pharmacological therapy can improve treatment [24].
Furthermore, specialised pain centres offering multi-
disciplinary evaluation and care have shown to be
highly efficacious and cost-effective [25]. We assume
that the offered additional non-pharmacological sup-
port from specially trained nurses in-between
follow-up visits, and support from psychologists,
physiotherapists has had an influence on the effective-
ness of the treatment. This has to be confirmed in
future studies.
Our results show a more favourable prognosis of TN,
than the prognosis of e.g. painful diabetic neuropathy. A
recent study of treatment of painful diabetic neuropathy
reported that only 30% of the patients, treated at a ter-
tiary centre, reported a good outcome, defined as a 30%
reduction of pain and 1-point reduction on the Pain
Interference Scale [26]. Whether the differences in
prognosis can be explained by the different etiologies,
different study designs or the different pharmacological
and non-pharmacological management has to be studied
in future studies.
Association between clinical characteristics and outcome
In a recent study, we found that the male sex and a neu-
rovascular contact with morphological changes of the
trigeminal nerve are strongly associated with a good out-
come of microvascular decompression [10]. Based on
these findings, we hypothesised that, in general, men
have a monofactorial etiology (neurovascular contact)
and women have a multifactorial etiology of TN. Inter-
estingly, none of the clinical characteristics (apart from a
long duration and co-existing chronic pain) was associ-
ated with a good outcome in the current study. These
findings could reflect that the pathophysiology of all pri-
mary TN patients is the same (disregarding the etiology);
hyperexcitable axons in the trigeminal nerve. Further-
more, the effects of medical treatment are also unrelated
to etiology of the disease.
Our results do show that patients with coexisting
chronic pain had poorer odds of a good outcome
than patients without coexisting chronic pain. This is
in line with previous studies demonstrating that com-
plex patients with multiple pain conditions are more
difficult to treat [27]. Another finding was the associ-
ation between long disease duration and good out-
come. Findings that contradicts what has previously
been proposed; that TN becomes refractory to
medical treatment, over time [2, 3]. However, since
this was not the primary aim of the study, these re-
sults should be confirmed in other studies before final
conclusions on these findings can be made.
Natural history of the disease
Our results show that TN does not generally seem to
progress. In our cohort, which might be expected to be
the most difficult to treat, only a small subset of patients
(apart from those referred to surgery) reported worsen-
ing of pain.
The current findings contradict the proposed natural
history theory of TN as a progressive disorder that, over
time will result in increased frequency and intensity of
pain concomitant persistent pain and sensory distur-
bances [28, 29]. The results of Rasmussen and colleagues
[6] also contradicts this theory of progressiveness as
concomitant persistent pain did not seem to be a
consequence of long-lasting paroxysmal pain; findings
that we later on confirmed [30]. A recent clinical
retrospective study also questions the theory, as only
a minority of TN patients had worsening of pain over
time, and only few patients became refractory to their
drug treatment [4].
Our results could reflect that the natural history of
TN is rather that of a non-progressive or slowly wearing
off nature, or the results could reflect a regression to-
wards the mean. To be able to make any final conclu-
sions on the natural history of the disease, RCTs and
even longer-term studies are needed. However, whatever
the explanation for the current results, the findings do
indicate that TN patients improve over a two-year
period given that they are managed in a multidisciplin-
ary setting directed by specialists, i.e. physicians, nurses,
psychologists and physiotherapists.
Relevant referral to neurosurgery
Our results are representative only for those TN patients
who were medically managed and not referred for sur-
gery. Fifty of those patients who were initially enrolled
in the management program were referred to Depart-
ment of Neurosurgery due to unsatisfactory manage-
ment of their TN pain. We recently reported a
favourable outcome for the selected group of TN
patients who underwent a microvascular decompression
at the Department of Neurosurgery [10]. The proportion
of patients referred to neurosurgery was considered in
line with what was recently reported by Zakrzewska et
al., describing the utilization patterns of 3685 newly di-
agnosed TN patients [31].
Current TN guidelines recommend that if carbamaze-
pine or oxcarbazepine treatment fails, patients are con-
sidered medically refractory and neurosurgical treatment
is the next step [11]. The results of our study underline
that optimisation of treatment should be done before pa-
tients are considered medically refractory. On the other
hand, referral to neurosurgery should probably be done
as soon as patients are considered medical refractory
considering the severity of TN pain. The current study
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does not answer the important question regarding the
optimal time for referral to surgery.
The patients with a poor outcome of the medical man-
agement in our cohort were all offered neurosurgical
treatment, but many opted out of surgery. We hypothe-
sise that it is either due to a relatively low overall burden
of pain or fear of surgery, that holds the patients back
for surgery. In Denmark healthcare is free why financial
problems is not a barrier to surgery.
Methodological considerations
The prospective design with standardised and systematic
assessments of the patients and the set up as a real-life
study in a clinical setting are the major strengths of this
study. Real world data is difficult to acquire but does
offer a more realistic view of the situation in the clinic
due to fewer exclusion criteria. Although treatment
practice was in line with international guidelines [11],
choice of medical therapy and when to refer to neuro-
surgery invariably depends on the local tradition and
patient preferences which probably varies according to
culture. The project was embedded in a busy clinical set-
ting and schemes to fill out were additional work for the
consulting physicians. This might be the cause of some
of the missing data.
The burden of overall pain was restricted to evaluate
the patients’ evaluation of the average pain frequency
and intensity, as opposed to a broader definition used by
Tölle et al. [13]. It represents a limitation of the study
that the BNI is a composite scale, why the interpreta-
tions of the results cannot be taken as a result of the in-
dividual units it is composed of (evaluation of pain and
medical treatment).
This study is hypothesis-generating regarding the
explanation of the favourable prognosis of TN. To be
able to explain the causes of favourable prognosis,
case-control studies or randomised controlled trials are
required. Although randomising TN patients into sub-
groups where some patients are not given any preventa-
tive drugs or the neurosurgical procedure is postponed,
would raise major ethical concerns. Future studies using
a similar methodology from other specialist centres, as
well as studies of even longer follow-up, are warranted
to produce more real-life data and shed light on progno-
sis, treatment and the natural history of TN.
Conclusion
This large prospective real-life study demonstrates that
patients enrolled in a structured multidisciplinary TN
management program at a specialist centre improve
considerably over time. Thus, TN does not seem to be a
disease with invariable progression in contrary to what
has previously been assumed. The reasons for improve-
ment could be several; optimisation of drug treatment,
continuous advice and education and support by the
multidisciplinary team, referral of the medically intract-
able patients for surgery or the natural history of the
disease. The favourable prognosis provides hope and op-
timism for patients and care providers and suggests that
specialist management of TN is highly rewarding.
Clinical implications
• In TN patients who are managed in a multidisciplinary
centre, the level of pain decreases over time and
medication dosages remain stable
• Prognosis in medically treated TN patients is not
dependent on concomitant persistent pain, neuroim-
aging findings or sex
• Findings indicate that TN is not an invariably
progressive disease and provides optimism and hope
to clinicians and patients that medical treatment of
TN by experts is highly rewarding
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